Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyArjun Vasant Balar, Ronald de Wit, Laurence E. Krieger et al.|The Lancet Oncology|2021Cited by 532
Tamoxifen-induced Radiation Recall DermatitisEric A. Singer, Daniel F. Hayes, Robert Warren et al.|The Breast Journal|2004Cited by 36
MP03-18 RESIDENT PERCEPTION OF A NOVEL LEADERSHIP BOOK CLUB CURRICULUMVivian C. Wong, Eric A. Singer, Cheryl Lee et al.|The Journal of Urology|2025Cited by 0